A Study for Therapeutic Treatment against Parkinson's Disease via Chou's 5-steps Rule

The enzyme L-DOPA decarboxylase (DDC), also called aromatic-L-amino-acid decarboxylase, catalyzes the biosynthesis of dopamine, serotonin, and trace amines. Its deficiency or perturbations in expression result in severe motor dysfunction or a range of neurodegenerative and psychiatric disorders. A D...

Full description

Saved in:
Bibliographic Details
Published inCurrent topics in medicinal chemistry Vol. 19; no. 25; p. 2318
Main Authors Lan, Jianqiang, Liu, Zhongqiang, Liao, Chenghong, Merkler, David J, Han, Qian, Li, Jianyong
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.01.2019
Subjects
Animals
Aromatic-L-Amino-Acid Decarboxylases - metabolism
Enzyme Inhibitors - chemistry
Enzyme Inhibitors - pharmacology
Humans
Molecular Structure
Neuroprotective Agents - chemistry
Neuroprotective Agents - pharmacology
Parkinson Disease - drug therapy
Parkinson Disease - enzymology
Parkinson Disease - metabolism
Aromatic-L-amino-acid decarboxylase
Biosynthesis
Inhibitor
Enzyme
Parkinson’s disease
L-DOPA decarboxylase
Online AccessGet more information

Cover

More Information
Summary:The enzyme L-DOPA decarboxylase (DDC), also called aromatic-L-amino-acid decarboxylase, catalyzes the biosynthesis of dopamine, serotonin, and trace amines. Its deficiency or perturbations in expression result in severe motor dysfunction or a range of neurodegenerative and psychiatric disorders. A DDC substrate, L-DOPA, combined with an inhibitor of the enzyme is still the most effective treatment for symptoms of Parkinson's disease. In this review, we provide an update regarding the structures, functions, and inhibitors of DDC, particularly with regards to the treatment of Parkinson's disease. This information will provide insight into the pharmacological treatment of Parkinson's disease.
ISSN:1873-4294
DOI:10.2174/1568026619666191019111528